DAWN News and Press, Day One Biopharmaceuticals Inc. From 11/17/22

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that man...

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced two upco...

Day One Biopharmaceuticals press release ( NASDAQ: DAWN ): Q3 GAAP EPS of -$0.53. Cash, cash equivalents and short-term investments totaled $374.3 million on September 30, 2022. Net loss totaled $37.8 million for the third quarter of 2022 compared to $19.2 million for ...

Topline results for full pivotal FIREFLY-1 study population with tovorafenib (DAY101) in relapsed or progressive pediatric low-grade glioma (pLGG) are expected in the first quarter of 2023 Strengthened leadership team with key appointments to senior management team and board of direct...

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that it ...

Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide markets. The COVID-19 pandemic has impacted the who...

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the app...

Summary Day One Biopharmaceuticals declared strong data in relapsed glioma in June. The company has strong cash position. They may submit an NDA next year. Day One Biopharmaceuticals, Inc. ( DAWN ) is a developer of targeted cancer therapies for a variety of tumo...

Day One Biopharmaceuticals press release ( NASDAQ: DAWN ): Q2 GAAP EPS of -$0.60. Cash, cash equivalents and short-term investments totaled $394.9 million on June 30, 2022. Based on current operating plan, management believes it has sufficient capital resources to fund ant...

Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline results for full pivotal study population expected in the first quarter of 2023 Expanded development of tovorafenib with initiation of p...